Investigation for Prostate Specific Antigene Expression of Endometrial Pathologies

Aim: The objective of study is to immunuhistochemically investigate and compare the expression of Prostate Specific Antigene (PSA) in proliferative endometrium, endometrial hyperplasia and endometrioid type endometrial carcinoma. Patients and Methods: 88 immunuhistochemical staining method performed hysterectomy specimen, diagnosed as proliferative endometrium (n:29), endometrial hyperplasia(n:28) and endometrioid type of endometrial carcinoma(n:31) were included in the study. A paraffin block showing the best pathology in each case was used for immunohistochemical staining with a prostate-specific antigen. The number of cells stained positively and the intensity of staining was determined semiquantitatively. For each case, the values of the two parameters (the number of positive cells and intensity of the staining) were multiplied, resulting in possible scores from 0 to 12. Result: PSA immunoreactivity was positive for 79,5% of all study hysterectomy specimens. Mean immunhistochemical staining score was 3,4±3 for proliferative endometrium group, 4,1±3 for endometrial hyperplasia group and 2,2±3 for endometrial carcinoma group. The difference for PSA expression score was not significant for groups. PSA expression was not significant for grade and stage of endometrial carcinoma. Conclusion: The results demonstrated the presence of PSA in most of the endometrial tissues. The expression is not significant for endometrial pathologies and suggests that it is not associated with endometrial carcinoma